MedTrace Logo

A Phase II Trial of Teclistamab in Participants With Previously Treated Immunoglobulin Light-chain (AL) Amyloidosis

NCT06649695 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2026-04-21

No results posted yet for this study

Summary

This is a multicenter open-label, phase 2 study in participant with previously treated immunoglobulin light-chain (AL) Amyloidosis to evaluate the benefit of teclistamab

Conditions

  • AL Amyloidosis

Interventions

DRUG

Teclistamab

Teclistamab will be administered via a subcutaneous injection (SC)

Sponsors & Collaborators

  • Janssen Research & Development

    collaborator UNKNOWN

  • European Myeloma Network B.V.

    lead NETWORK

Principal Investigators

  • Murielle Roussel, MD · CHU Limoges

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-07-02
Primary Completion
2028-09-30
Completion
2028-09-30
FDA Drug
Yes

Countries

  • Australia
  • France
  • Germany
  • Greece
  • Italy
  • Netherlands

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06649695 on ClinicalTrials.gov